Clinically, immunostaining of high-grade serous ovarian cancer showed higher levels of RAD51C protein compared to benign tumors, and increased RAD51C levels were associated with higher clinical staging and poorer prognosis [97]. The gene discussed is RAD51C; the disease is benign neoplasm.